Research programme: CNS disorder liposomal therapeutics - Sihuan/BBB Therapeutics

Drug Profile

Research programme: CNS disorder liposomal therapeutics - Sihuan/BBB Therapeutics

Alternative Names: Glutathione-pegylated liposomal therapeutics - Sihuan/to-BBB

Latest Information Update: 03 Oct 2014

Price : $50

At a glance

  • Originator Sihuan Pharmaceutical Holdings Group; to-BBB technologies
  • Developer BBB Therapeutics; Sihuan Pharmaceutical Holdings Group
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research CNS disorders

Most Recent Events

  • 30 Sep 2014 to-BBB technologies is now called BBB Therapeutics
  • 12 Feb 2014 Profile released, added ADMN.
  • 11 Dec 2013 Early research in CNS disorders in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top